---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-058762"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:52:49.671184+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q1 net loss $31.3M; cash $334.8M; CNTY-101 data expected by year end

## Summary
- Q1 net loss $31.3M vs $37.5M prior year; R&D expenses $24.9M, G&A $8.9M.
- Cash, equivalents, investments $334.8M as of March 31, 2023; cash runway into 2026.
- CNTY-101 Phase 1 ELiPSE-1 trial ongoing; initial data from Schedule A expected by year end 2023.
- FY2023 GAAP operating expense guidance $135-145M; non-cash stock comp $12-17M.
- Leadership: Greg Russotti interim CEO (since March), Michael Diem CFO, Hy Levitsky President of R&D.

## SEC filing metadata
- accession: 0001104659-23-058762
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465923058762/0001104659-23-058762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465923058762/tm2315313d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-058762
- JSON: https://secwatch.observer/filing/0001104659-23-058762.json
- Plain text: https://secwatch.observer/filing/0001104659-23-058762.txt

## Key facts
- Earnings Releases
  Century Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $1.7 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $1.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: of $122.1 million). · Collaboration Revenue: Collaboration revenue generated through the Company’s collaboration, option and license agreement with Bristol-Myers Squibb was $1.7 million for the three months ended March 31, 2023, compared to $1.1 million for the same period in 2022. · Research and Development (R&D) expenses : R&D expenses were $24.9 million for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465923058762/0001104659-23-058762-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.